Types segmentation distinguishes sIPV products according to antigenic composition and formulation: monovalent, trivalent, and combination (e.g., sIPV co‑administered with DTP). Monovalent sIPV contains a single poliovirus serotype and is primarily employed in targeted outbreak containment where a specific serotype predominates; its market contribution is limited by narrow indication but commands premium pricing. Trivalent sIPV incorporates all three serotypes (type 1, 2, 3) and underpins routine immunization schedules, thereby representing the core volume driver in the market. Combination formulations integrate sIPV with other pediatric vaccines to reduce injection burden, fostering uptake in integrated immunization programs and expanding market penetration in low‑resource settings. The relative share of each type is shaped by regulatory approvals, manufacturing capacity, and programmatic preferences, influencing overall market size. Understanding the market taxonomy of sIPV types assists manufacturers and policymakers in forecasting demand, optimizing product pipelines, and aligning supply strategies with public‑health objectives. In regions where combination vaccines are prioritized, the share of combination sIPV can exceed 40 % of total doses, reshaping the revenue composition toward higher-volume, lower-margin sales.
